Literature DB >> 18393368

Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.

M Sasaki1, J Yamaguchi, K Itatsu, H Ikeda, Y Nakanuma.   

Abstract

Polycomb group protein EZH2 and Bmi1 are reportedly involved in the progression of malignant tumours. We examined the participation of EZH2 in multi-step cholangiocarcinogenesis in hepatolithiasis with respect to tumour suppressor gene p16 INK4a. We examined 20 hepatolithiatic livers with intrahepatic cholangiocarcinoma (ICC) and 10 histologically normal livers. Neoplastic biliary lesions were classified into biliary intraepithelial neoplasm (BilIN-1, 2 and 3) and invasive carcinoma. We selected 15 foci of invasive carcinoma, 8 BilIN-3 (carcinoma in situ), 12 BilIN-2 (high-grade dysplasia), 32 BilIN-1 (low-grade dysplasia) and 37 non-neoplastic biliary epithelia from these livers. Expression of p16 INK4a, EZH2 and Bmi1 were surveyed in these foci. P16 INK4a promoter methylation was examined in microdissected tissues. Taking advantage of two cell lines of CC (HuCTT-1 and TFK-1) and small interfering RNA (siRNA), the effects of the knockdown of EZH2 on p16 INK4a methylation of CC cells were examined. Expression of p16 INK4a, which was frequent in BilIN1, was decreased in BilIN-2/3 and invasive carcinoma, while EZH2 expression showed step-wise increase from BilIN-1, -2 and -3 to invasive carcinoma (p < 0.01). P16 INK4a promoter hypermethylation was related to aberrant expression of EZH2. The knockdown of EZH2 in cultured CC cells decreased p16 INK4a methylation and decreased binding of EZH2 to the p16 INK4a gene promoter. The latter suggested that direct binding of EZH2 is involved in the regulation of the p16 INK4a gene. Our data suggest that over-expression of EZH2 may induce hypermethylation of p16 INK4a promoter followed by decreased expression of p16 INK4a in the multi-step cholangiocarcinogenesis through intraepithelial neoplasm in hepatolithiasis. Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393368     DOI: 10.1002/path.2345

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  33 in total

1.  CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma.

Authors:  Baek-hui Kim; Nam-Yun Cho; So Hyun Shin; Hyeong-Ju Kwon; Ja June Jang; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2009-09-10       Impact factor: 4.064

2.  Histone modifiers in cancer: friends or foes?

Authors:  Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal:  Genes Cancer       Date:  2011-06

3.  Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells.

Authors:  Joseph E Gergely; Armond E Dorsey; Goberdhan P Dimri; Manjari Dimri
Journal:  Mol Carcinog       Date:  2018-03-25       Impact factor: 4.784

4.  Aberrant DNA methylation profile in cholangiocarcinoma.

Authors:  Li Huang; Gabriel Frampton; Li-Jian Liang; Sharon Demorrow
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 5.  Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia.

Authors:  Yasunori Sato; Motoko Sasaki; Kenichi Harada; Shinichi Aishima; Toshio Fukusato; Hidenori Ojima; Yae Kanai; Masayoshi Kage; Yasuni Nakanuma; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2013-04-25       Impact factor: 7.527

6.  Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha.

Authors:  Keita Itatsu; Motoko Sasaki; Junpei Yamaguchi; Shusaku Ohira; Akira Ishikawa; Hiroko Ikeda; Yasunori Sato; Kenichi Harada; Yoh Zen; Hiroshi Sato; Tetsuo Ohta; Masato Nagino; Yuji Nimura; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

7.  Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer.

Authors:  Jun Wang; Fang Huang; Jian Huang; Jindan Kong; Shenglan Liu; Jun Jin
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

Review 8.  H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Authors:  J N Nichol; D Dupéré-Richer; T Ezponda; J D Licht; W H Miller
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

Review 9.  Hepatolithiasis and intrahepatic cholangiocarcinoma: A review.

Authors:  Hyo Jung Kim; Jae Seon Kim; Moon Kyung Joo; Beom Jae Lee; Ji Hoon Kim; Jong Eun Yeon; Jong-Jae Park; Kwan Soo Byun; Young-Tae Bak
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

10.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

Authors:  Warren Fiskus; Yongchao Wang; Arun Sreekumar; Kathleen M Buckley; Huidong Shi; Anand Jillella; Celalettin Ustun; Rekha Rao; Pravina Fernandez; Jianguang Chen; Ramesh Balusu; Sanjay Koul; Peter Atadja; Victor E Marquez; Kapil N Bhalla
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.